Targeted mutations in IFNα2 improve its antiviral activity against various viruses.

doi:10.1128/mbio.02357-23

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Targeted mutations in IFNα2 improve its antiviral activity against various viruses.

mBio - 19 Dec 2023

Karakoese Zehra, Le-Trilling Vu-Thuy Khanh, Schuhenn Jonas, Francois Sandra, Lu Mengji, Liu Jia, Trilling Mirko, Hoffmann Daniel, Dittmer Ulf, Sutter Kathrin

Abstract excerpt

IMPORTANCE: The potency of interferon (IFN)α to restrict viruses was already discovered in 1957. However, until today, only IFNα2 out of the 12 distinct human IFNα subtypes has been therapeutically used against chronic viral infections. There is convincing evidence that other IFNα subtypes are far more efficient than IFNα2 against many viruses. In order to identify critical antiviral residues within the IFNα...

Topics

Antiviral Agents
Humans
Interferon-alpha
Mutation
Receptor, Interferon alpha-beta
Hepatitis B virus
Interferon alpha-2
HIV
Protein Binding
Viruses

Source

Open in PubMed Open full text

Identifiers

PMID: 37874130
DOI: 10.1128/mbio.02357-23
PMCID: PMC10746204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics